ImmunityBio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 628
- Market Cap
- $2.9B
- Website
- http://www.immunitybio.com
- Introduction
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong ...
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
Phase 2
Withdrawn
- Conditions
- Interventions
- Drug: LeucovorinDrug: 5-FluorouracilDrug: Doxorubicin HCLDrug: paclitaxelDrug: Aldoxorubicin HClDrug: nab-PaclitaxelBiological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Drug: AvelumabBiological: ALT-803Biological: haNKDrug: Cyclophosphamide
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03554109
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.
Phase 3
Active, not recruiting
- Conditions
- Interventions
- Drug: N-803 + PembrolizumabDrug: N-803 + Carboplatin + Nab-paclitaxel + PembrolizumabDrug: N-803 + Cisplatin or Carboplatin + Pembrolizumab + PemetrexedDrug: PembrolizumabDrug: Carboplatin + Nab-paclitaxel or Paclitaxel + PembrolizumabDrug: Cisplatin or Carboplatin + Pembrolizumab + PemetrexedDrug: N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 1538
- Registration Number
- NCT03520686
- Locations
- 🇺🇸
Oncology Consultants, PA, Houston, Texas, United States
🇺🇸Adventist Health White Memorial, Los Angeles, California, United States
🇺🇸Genesis Cancer Center, Hot Springs, Arkansas, United States
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
Phase 1
Terminated
- Conditions
- Interventions
- Drug: Aldoxorubicin HClBiological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionDrug: AvelumabDrug: bevacizumabDrug: CapecitabineDrug: CetuximabDrug: CisplatinDrug: CyclophosphamideDrug: FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: NecitumumabProcedure: SBRTBiological: N-803
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387111
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
Phase 1
Terminated
- Conditions
- Interventions
- Drug: Aldoxorubicin HClBiological: N-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for InfusionBiological: avelumabBiological: bevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelProcedure: SBRT
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03387085
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387098
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03329248
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.055: a Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with Immune Checkpoint Inhibitors
Phase 2
Recruiting
- Conditions
- Interventions
- Drug: N-803 + PembrolizumabDrug: N-803 + Pembrolizumab + PD-L1 t-haNKDrug: N-803 + Docetaxel + PembrolizumabDrug: N-803 + NivolumabDrug: N-803 + Nivolumab + PD-L1 t-haNKDrug: N-803 + Docetaxel + NivolumabDrug: N-803 + AtezolizumabDrug: N-803 + Atezolizumab + PD-L1 t-haNKDrug: N-803 + AvelumabDrug: N-803 + Avelumab + PD-L1 t-haNKDrug: N-803 + DurvalumabDrug: N-803 + Durvalumab + PD-L1 t-haNK
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03228667
- Locations
- 🇺🇸
Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineDrug: cisplatinDrug: cyclophosphamideDrug: 5Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab-paclitaxelDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197571
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
Phase 1
Withdrawn
- Conditions
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CyclophosphamideDrug: 5-fluorouracilDrug: FulvestrantDrug: LeucovorinDrug: PaclitaxelDrug: omega-3 acid ethyl estersDrug: OxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6301Biological: haNK®
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197584
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
Phase 1
Withdrawn
- Conditions
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineDrug: cisplatinDrug: cyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-paclitaxelDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03175666
© Copyright 2024. All Rights Reserved by MedPath